Ann: ATH Presentation Tracking MSA Progression at Intl Symposium, page-24

I remember when I first joined this group, there was conjecture about wether there will be or wont be a phase 3.

Some were saying no as its a needed drug that works, as there is currently no treatment for MSA and its ODD supports there not needing to be a phase 3, which is also supported with online readings. Than others were saying it will be needed.

But that all comes down to the FDA, than also what will the EMA and TGA say.

The mounting evidence I would assume would support a no need phase 3, but may also assist with other branching studies.

With that I was also thinking, if or when Alterity does branch to other neurodegenerate diseases, they should automatically bypass phase 1 as it is known to be safe, therefore should start all future studies in phase II.

Also, just seen this print by Stock head:

https://www.google.com/amp/s/**promotion blocked**/health/health-check-prestigious-publication-supports-alteritys-iron-overload-in-the-brain-thesis/%3famp